Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder (MATRIX)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Watson Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00224146
First received: September 14, 2005
Last updated: November 29, 2011
Last verified: November 2011

September 14, 2005
November 29, 2011
May 2004
May 2005   (final data collection date for primary outcome measure)
Change in health-related quality of life [ Designated as safety issue: No ]
Change in health-related quality of life
Complete list of historical versions of study NCT00224146 on ClinicalTrials.gov Archive Site
  • Change in other outcomes such as: [ Designated as safety issue: No ]
  • depression [ Designated as safety issue: No ]
  • work productivity [ Designated as safety issue: No ]
  • participant satisfaction [ Designated as safety issue: No ]
  • effect of enhanced patient education on any of the above outcomes [ Designated as safety issue: No ]
  • Change in other outcomes such as:
  • depression
  • work productivity
  • participant satisfaction
  • effect of enhanced patient on any of the above outcomes
Not Provided
Not Provided
 
Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive Bladder
Multicenter Assessment of Transdermal Therapy in Overactive Bladder With Oxybutynin TDS (MATRIX)

This study evaluates changes in health related quality of life outcomes in patients using Oxytrol(r)

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Overactive Bladder
  • Urinary Incontinence
  • Quality of Life
Drug: oxybutynin transdermal delivery system (Oxytrol(r))
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2878
May 2005
May 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients with one or more symptom of overactive bladder, including urge urinary incontinence, urgency and/or frequency

Exclusion Criteria:

  • Patients for whom Oxytrol(r) is contraindicated.
  • Patients treated with Oxytrol(r) prior to participation in this study.
  • Patients residing in long-term care facilities or nursing homes.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00224146
OXY0402, MATRIX
Not Provided
Watson Pharmaceuticals
Watson Pharmaceuticals
Not Provided
Study Director: Naomi V. Dahl, PharmD Watson Laboratories, Inc.
Watson Pharmaceuticals
November 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP